2012—2022年北京市丰台区利福平耐药肺结核患者流行病学特征分析  

Epidemiological characteristics of patients with rifampicin-resistant pulmonary tuberculosis in Fengtai District of Beijing from 2012 to 2022

作　　者：薛晓[1] 张东彦[1] 贾雪娇 胡远莲 艾萍 陈巍[1] 邓玲 杨国梁 董洋洋 XUE Xiao;ZHANG Dongyan;JIA Xuejiao;HU Yuanlian;AI Ping;CHEN Wei;DENG Ling;YANG Guoliang;DONG Yangyang(Fengtai District Center for Disease Control and Prevention,Beijing 100070,China)

机构地区：[1]北京市丰台区疾病预防控制中心,北京100070

出　　处：《预防医学情报杂志》2025年第1期8-13,共6页Journal of Preventive Medicine Information

摘　　要：目的了解北京市丰台区利福平耐药肺结核患者的流行病学特征、治疗情况及丰台区耐药筛查情况,为耐药结核病防控工作提供科学依据。方法对全民健康保障信息化工程“中国疾病预防控制信息系统”子系统“监测报告管理”中登记的2012—2022年现住址为北京市丰台区的利福平耐药肺结核患者流行病学特征、纳入治疗及治疗转归情况进行描述,并对影响治疗转归的因素进行分析。对2019—2022年丰台区的耐药筛查情况进行描述。利用SPSS 19.0软件,率的比较采用卡方检验,以P<0.05为差异有统计学意义。结果2012—2022年北京市丰台区共登记利福平耐药肺结核患者126例,年平均登记率为0.52/10万,登记率呈上升趋势(χ_(趋势)^(2)=28.500,P<0.001)。市级定点医疗机构收治94例(74.60%),区级定点医疗机构收治32例(25.40%);男性88例(69.84%),女性38例(30.16%),男女性别比2.32∶1;年龄分布中以45~64岁年龄组最多(54例,42.86%);职业分布中以家务及待业最多(53例,42.06%);户籍分布以本地患者居多(76例,60.32%);登记分类以初治患者居多(82例,65.08%);地区分布以东中片患者居多(115例,91.27%)。北京市丰台区利福平耐药肺结核患者纳入治疗率为93.65%,成功治疗率为73.81%。年龄越大,成功治疗率越低(χ_(趋势)^(2)=9.485,P=0.002)。2019—2022年丰台区新病原学阳性患者耐药筛查率分别为92.25%、97.44%、93.88%和97.01%,高危人群耐药筛查率分别为92.86%、100.00%、94.12%和100.00%。结论应加强区级定点医院的能力建设,提高区域收治能力;重点关注男性、中年人群、家务及待业人群等;关注初治肺结核患者耐药监测,加强耐药患者发现工作;治疗过程中要重点关注老年人群,采取综合措施提高患者纳入治疗率和成功治疗率。Objective To explore the epidemiological characteristics,treatment and drug resistance screening of patients with rifampicin-resistant pulmonary tuberculosis in Fengtai District of Beijing,and to provide scientific reference for the prevention and control of drug-resistant tuberculosis.Methods The epidemiological characteristics,treatment inclusion and treatment outcome of rifampicinresistant pulmonary tuberculosis patients whose current address were Fengtai District of Beijing registered in the Suveillance Report Management Model,a subsystem of the“China Information System For Disease Control and Prevention”of the national health security information project from2012 to 2022 were described,and the influencing factors of treatment outcome were analyzed.The status of drug resistance screening in Fengtai District from 2019 to 2022 was described.SPSS 19.0software was used.Chi-square test was used to compare the rates,and P<0.05 was considered statistically significant.Results A total of 126 rifampicin-resistant pulmonary tuberculosis cases were registered in Fengtai District of Beijing from 2012 to 2022,with an average annual registration rate of 0.52/105.The registration rate showed an increasing trend(χ_(trend)^(2)=28.500,P<0.001).Municipal tuberculosis designated hospitals registered 94 cases(74.60%),and local tuberculosis designated hospitals registered 32 cases(25.40%).There were 88 male cases(69.84%)and 38 female cases(30.16%),with a male to female sex ratio of 2.32∶1.The patients were mainly concentrated in the age group 45-64 years old(54 cases,42.86%).In the occupation distribution,the household and unemployed were the most(53 cases,42.06%).Most of the patients were local residents(76 cases,60.32%).The majority of registered patients were initially treated(82 cases,65.08%).Most patients were in the east and middle areas of Fengtai District(115 cases,91.27%).The treatment inclusion rate of rifampicin-resistant tuberculosis patients in Fengtai District of Beijing was93.65%,and the successful treatment

关 键 词：利福平耐药 肺结核 流行病学 

分 类 号：R521[医药卫生—内科学]